ALX Oncology Holdings Inc. ALXO
Set alert
At close · Oct 30
After hours · Oct 30, 6:40 PM ET
- YTD
- +7.96%
- 1 year
- -21.29%
- Open
- 1.20
- Prev close
- 1.22
- Mkt cap
- 168.70M
- Vol
- 422.20K
- Avg vol
- 1.27M
- EPS
- -1.13
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.20
- High
- 1.26
- Forward P/E
- -0.68
- Beta
- 1.04
- Short ratio
- 8.58
- Inst. own
- 88.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.50
- 200-d avg
- 6.33
- 1y target
- 7.67
5D chart
Signals (59)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 12:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:45 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:20 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:10 PM | 3 days ago |
| RSI: Overbought | Oct 29, 2:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:10 PM | 4 days ago |
| RSI: Overbought | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:50 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:15 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:40 PM | 6 days ago |
| RSI: Overbought | Oct 26, 2:40 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:25 PM | 6 days ago |
Key statistics
- Market cap
- 96.52M
- Enterprise value
- -45.77M
- Trailing P/E
- 0.00
- Forward P/E
- -0.68
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.71
- EPS (TTM)
- -2.97
- Beta
- 1.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -74.55M
- Total cash
- 148.57M
- Total debt
- 17.36M
- Return on equity
- -98.94%
- Shares outstanding
- 52.74M
- Short % of float
- 23.56%
- 50-day average
- 1.50
- 200-day average
- 6.33
Analyst view
Consensus: buy
- Target (low)
- 2.00
- Target (mean)
- 7.67
- Target (high)
- 25.00
- Strong buy2
- Buy2
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.38766.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.78 | -0.58 | +0.20 | +25.64% |
| Aug 8, 2024 | Jun 1, 2024 | -0.77 | -0.76 | +0.01 | +1.30% |
| Aug 8, 2024 | Jun 1, 2024 | -0.77 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.87 | -0.71 | +0.16 | +18.39% |
| May 9, 2024 | Mar 1, 2024 | -0.87 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -0.84 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Jefferies | down | Buy | Hold |
| Dec 18, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Dec 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 12, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Aug 16, 2024 | UBS | main | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alxoncology.com
News
- 12 Health Care Stocks Moving In Friday's Intraday Session
- ALX Oncology Holdings Announces Publication Of Clinical Data From Its ASPEN-06 Randomized Phase 2 Clinical Trial In Nature Medicine, Showing Durable Clinical Benefit With Evorpacept In HER2-Positive Gastric Cancer
- ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
- 7,399,530 Shares in ALX Oncology Holdings Inc. $ALXO Acquired by BlackRock Inc.
- ALX Oncology to Present at Upcoming Investor Conferences in September
- 5AM Venture Management LLC Makes New Investment in ALX Oncology Holdings Inc. $ALXO
- Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
- ALX Oncology Holdings Q2 Adj. EPS $(0.11) Beats $(0.14) Estimate
- ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Your note
Sign in to keep a note on ALXO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GARCIA PETER S | Chief Financial Officer | Purchase | Jun 12, 2024 | 122,348 |
| HEMRAJANI REKHA | Director | Purchase | Dec 1, 2024 | 33,000 |
| LETTMANN JASON | Chief Executive Officer | Purchase | Mar 13, 2024 | 171,620 |
| PINTO SHELLY | Officer | Sale | Aug 13, 2024 | 91,549 |
| PONS JAUME | President | Sale | Aug 13, 2024 | 591,510 |
| RANDOLPH SOPHIA | Officer | Sale | Aug 13, 2024 | 325,711 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| venBio Partners LLC | 18.39% | 9,699,925 | 17.75M | Sep 29, 2024 |
| FMR, LLC | 11.12% | 5,865,106 | 10.73M | Sep 29, 2024 |
| Tang Capital Management, LLC | 7.97% | 4,204,735 | 7.69M | Sep 29, 2024 |
| Vivo Capital, LLC | 7.65% | 4,034,522 | 7.38M | Sep 29, 2024 |
| Redmile Group, LLC | 7.27% | 3,836,576 | 7.02M | Sep 29, 2024 |
| Blackrock Inc. | 4.93% | 2,601,776 | 4.76M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Small Cap Growth Fund | 3.20% | 1,689,620 | 3.09M | Aug 30, 2024 |
| Fidelity Series Small Cap Opportunities Fund | 2.00% | 1,057,220 | 1.93M | Aug 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.87% | 984,586 | 1.80M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.64% | 867,199 | 1.59M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 1.58% | 835,504 | 1.53M | Oct 30, 2024 |
| Fidelity Small Cap Growth K6 Fund | 1.18% | 621,497 | 1.14M | Aug 30, 2024 |